Improved Isolation of Dendritic Cells in Chronic Arthritic Joints Reveals No B7 (CD80) Surface Expression

Summers, Kelly L.; O’Donnell, John L.; Daniels, P.; Hart, Derek N.J.

doi:10.1007/978-1-4615-1971-3_126

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since CD28 is the prototypic T cell costimulatory receptor, CD28 ligands on synovial DC have potential importance. CD80 has been reported as absent (87)(88) or, more likely, only weakly present on synovial fluid and tissue DC (68,(81)(82)84). CD86 is expressed a bit more strongly, is readily upregulated in vitro, and is functionally important in stimulation of T cells by these DC (81)(82).…”

Section: Identification and Characterization Of Dendritic Cells In Rh...mentioning

confidence: 99%

Dendritic cells in rheumatoid arthritis

Sarkar

Fox

2005

Front Biosci

View full text Add to dashboard Cite

Dendritic cells are the most potent subset of antigen presenting cells. They are derived from bone marrow stem cells and reside in peripheral tissues or blood. Upon exposure to antigens and cytokines the peripheral DC s, express high amounts of peptide-MHC, and upregulate their costimulatory molecules, migrate to draining lymph nodes, and interact with T cells to stimulate or tolerize them. Dendritic cells have been found in synovium and joint fluid in rheumatoid arthritis, often at the center of a cluster of T cells. These DC s express MHC II, the costimulatory molecules CD40, CD80, CD86, adhesion molecules such as DC-SIGN and chemokine receptors such as CCR7. DC s can polarize T cells into Th1 or Th2 phenotypes depending on the cytokine environment. Th1 responses are initiated in context of IL-12 and IL-23. The cytokine milieu of the RA synovium promotes DC differentiation and function that could lead to autoantigen presentation to T cells. Dendritic cells may be central to the pathogenesis of RA and could also be logical targets for treatment. DC s themselves could be used to deliver therapeutic gene products in autoimmune disease. DC s genetically modified to express IL-4 have been used to treat or prevent collagen arthritis in mice.

show abstract